Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 8/20 | 0.80 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.72 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.72 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.72 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.67 |
| ▸ | TGFBR1 | P36897 | 10/20 | 0.54 |
| ▸ | TGFBR2 | P37173 | 7/20 | 0.54 |
| ▸ | MET | P08581 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2883634 | 0.91 | MAPK14 (0.81) | MAPK14MAPK13MAPK12MAPK11PRKD1 | |
| SCHEMBL2890929 | 0.89 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11PRKD1 | |
| SCHEMBL2891170 | 0.87 | MAPK14 (0.72) | MAPK14MAPK13MAPK12MAPK11PRKD1 | |
| SCHEMBL2887280 | 0.87 | MAPK14 (0.94) | MAPK14MAPK13MAPK12MAPK11PRKD1 | |
| SCHEMBL2891138 | 0.86 | MAPK14 (0.76) | MAPK14MAPK13MAPK12MAPK11PRKD1 | |
| SCHEMBL12444981 | 0.84 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11PRKD1 | |
| SCHEMBL27784832 | 0.82 | MAPK14 (0.68) | MAPK14MAPK13MAPK12MAPK11PRKD1 | |
| SCHEMBL2892846 | 0.80 | TGFBR1 (0.80) | MAPK14MAPK13MAPK12MAPK11PRKD1 | |
| SCHEMBL2886849 | 0.77 | MAPK14 (0.70) | MAPK14MAPK13MAPK12MAPK11PRKD1 | |
| SCHEMBL2000094 | 0.75 | MAPK14 (0.61) | MAPK14MAPK13MAPK12MAPK11PRKD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100184598-A1 | 4-AZA INDOLE DERIVATIVES AND THEIR USE AS FUNGICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2010-07-22 | — | — | US | claimed |
| CN-101784191-A | 4-aza indole derivatives and their use as fungicides | SYNGENTA PARTICIPATIONS AG | 2010-07-21 | — | — | CN | claimed |
| EP-2136640-A2 | 4-AZA INDOLE DERIVATIVES AND THEIR USE AS FUNGICIDES | Syngeta Participations AG (CH) | 2009-12-30 | — | — | EP | claimed |
| WO-2008132434-A2 | 4-AZA INDOLE DERIVATIVES AND THEIR USE AS FUNGICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2008-11-06 | — | — | WO | claimed |
| US-8084395-B2 | 4-aza indole derivatives and their use as fungicides | SYNGENTA CROP PROTECTION, INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-20100184598-A1 | 4-AZA INDOLE DERIVATIVES AND THEIR USE AS FUNGICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2010-07-22 | — | — | US | disclosed |
| CN-101784191-A | 4-aza indole derivatives and their use as fungicides | SYNGENTA PARTICIPATIONS AG | 2010-07-21 | — | — | CN | disclosed |
| EP-2136640-A2 | 4-AZA INDOLE DERIVATIVES AND THEIR USE AS FUNGICIDES | Syngeta Participations AG (CH) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008132434-A2 | 4-AZA INDOLE DERIVATIVES AND THEIR USE AS FUNGICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2008-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184598-A1 | 4-AZA INDOLE DERIVATIVES AND THEIR USE AS FUNGICIDES | IDO1, INMT, AZI2 | MAPK14 512/4885MAPK13 1175/4885MAPK12 1405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.